Biotech Industry Examiner

Menu
Menu
subscribe now
Search
AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity

AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity

AstraZeneca has inked a deal worth “up to” $555 million

Dermatology’s next play: bispecifics that shut down OX40L and TNF

Dermatology’s next play: bispecifics that shut down OX40L and TNF

Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is

Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion

Pharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 Billion

Eli Lilly and Company, a global leader in pharmaceutical development,

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins

When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials

When the FDA Starts Trusting Algorithms: What AIM-NASH Means for Liver Drug Trials

The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here

The anti-ageing bet on the liver: why longevity biotech’s first real drugs may start here

From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care

From California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome Care

A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong

A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong

MOST POPULAR

News

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top